IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.416
EU - Europa 13.067
AS - Asia 7.918
SA - Sud America 1.637
Continente sconosciuto - Info sul continente non disponibili 639
AF - Africa 361
OC - Oceania 15
Totale 42.053
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.136
RU - Federazione Russa 2.643
SG - Singapore 2.583
CN - Cina 2.521
IT - Italia 2.512
GB - Regno Unito 2.340
IE - Irlanda 1.685
BR - Brasile 1.349
UA - Ucraina 860
VN - Vietnam 858
SE - Svezia 807
FR - Francia 801
HK - Hong Kong 637
DE - Germania 576
FI - Finlandia 379
KR - Corea 344
IN - India 193
BD - Bangladesh 171
ZA - Sudafrica 159
CA - Canada 142
NL - Olanda 105
TR - Turchia 101
AR - Argentina 94
IQ - Iraq 85
MX - Messico 66
NG - Nigeria 66
JP - Giappone 65
PL - Polonia 59
ID - Indonesia 53
ES - Italia 50
EC - Ecuador 46
AT - Austria 41
BE - Belgio 39
MA - Marocco 34
CO - Colombia 33
SA - Arabia Saudita 32
CL - Cile 31
PK - Pakistan 30
UZ - Uzbekistan 30
VE - Venezuela 29
CZ - Repubblica Ceca 28
KE - Kenya 24
IR - Iran 23
LT - Lituania 23
PY - Paraguay 23
JO - Giordania 20
EG - Egitto 18
MY - Malesia 17
NP - Nepal 17
PE - Perù 17
JM - Giamaica 16
AU - Australia 15
KZ - Kazakistan 15
RS - Serbia 15
TN - Tunisia 15
AZ - Azerbaigian 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
CI - Costa d'Avorio 12
CR - Costa Rica 12
OM - Oman 12
AL - Albania 10
DZ - Algeria 10
PH - Filippine 10
PT - Portogallo 10
BO - Bolivia 9
DO - Repubblica Dominicana 9
IL - Israele 9
TH - Thailandia 9
TW - Taiwan 9
EE - Estonia 8
LB - Libano 8
PS - Palestinian Territory 8
SC - Seychelles 8
BG - Bulgaria 7
EU - Europa 7
KG - Kirghizistan 7
RO - Romania 7
TT - Trinidad e Tobago 7
DK - Danimarca 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
BA - Bosnia-Erzegovina 5
ET - Etiopia 5
GR - Grecia 5
GT - Guatemala 5
HN - Honduras 5
PA - Panama 5
UY - Uruguay 5
BY - Bielorussia 4
LK - Sri Lanka 4
NI - Nicaragua 4
BB - Barbados 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
NO - Norvegia 3
BH - Bahrain 2
Totale 41.386
Salva come PNG Salva come JPEG
Città #
Fairfield 2.027
Southend 1.984
Dallas 1.969
Dublin 1.662
Ashburn 1.390
Singapore 1.371
Woodbridge 988
Chandler 810
Santa Clara 794
Seattle 788
Houston 787
Wilmington 769
Moscow 737
Jacksonville 735
Milan 685
Cambridge 638
San Jose 628
Beijing 617
Hong Kong 616
Council Bluffs 524
Hefei 424
Ann Arbor 410
Princeton 371
Seoul 340
Siena 327
The Dalles 292
Los Angeles 268
Ho Chi Minh City 264
Nanjing 249
Rome 248
Lauterbourg 220
Helsinki 196
Hanoi 188
New York 150
Munich 136
Johannesburg 132
San Mateo 132
Columbus 129
São Paulo 126
Florence 124
Buffalo 122
Boardman 111
San Diego 107
Dong Ket 88
Shanghai 84
Nanchang 77
London 76
Orem 67
Abuja 63
Dearborn 63
Figino 57
Redondo Beach 56
Shenyang 56
Tokyo 51
Bengaluru 50
Menlo Park 50
San Francisco 50
Nuremberg 49
Hebei 48
Turin 48
Turku 48
Chicago 47
Izmir 47
Tianjin 46
Warsaw 45
Frankfurt am Main 44
Toronto 43
Lappeenranta 41
Phoenix 41
Jiaxing 38
Stockholm 37
Brooklyn 36
Denver 36
Kunming 36
Atlanta 35
Bologna 35
Baghdad 34
Brussels 34
Da Nang 34
Naples 34
Montreal 32
Rio de Janeiro 32
Boston 30
Changsha 29
Chennai 29
Dhaka 28
Tashkent 28
Belo Horizonte 27
Curitiba 27
Norwalk 26
Zhengzhou 26
Haiphong 25
Mexico City 25
Amsterdam 23
Brasília 23
Porto Alegre 23
Guangzhou 22
Poplar 22
Miami 21
Portsmouth 21
Totale 27.928
Salva come PNG Salva come JPEG
Nome #
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 349
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 347
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 341
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 338
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 331
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 320
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 318
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 304
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 300
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 299
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 298
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 297
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 296
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 296
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 294
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 291
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 284
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 283
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 277
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 274
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 272
Second generation proteasome inhibitors in multiple myeloma 267
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 261
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 260
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 259
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 257
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 257
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 256
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 255
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 254
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 248
Central nervous system multiple myeloma 246
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 245
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 241
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 240
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 236
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 234
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 232
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 230
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 230
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 230
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 227
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 225
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 224
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 222
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 222
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 219
Treatment of smoldering multiple myeloma 218
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 218
FLT3 inhibitors in the management of acute myeloid leukemia 218
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 217
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 216
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 215
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 215
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 213
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 211
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 211
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 210
Daratumumab efficacy in extramedullary orbital myeloma 209
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 208
Anti CD38 monoclonal antibodies for multiple myeloma treatment 208
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 207
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 207
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 206
Evolving treatments in multiple myeloma patients with renal failure 205
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 204
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study 204
Extramedullary myeloma relapses 203
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 203
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 203
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 203
An unusual presentation of chronic B-cell lymphocytic leukaemia 202
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 202
Hyperlipidemia in a myeloma patient after bortezomib treatment 201
Predicting the clinical course of Hodgkin lymphoma 199
Bcr-abl peptides for chronic myeloid leukemia. 196
The effects of zoledronic acid on serum lipids in multiple myeloma patients 194
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 193
Unusual localizations of plasmacytoma 193
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 192
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 192
Speckle tracking echocardiography in plasma cell disorders: The role of advanced imaging in the early diagnosis of AL systemic cardiac amyloidosis 191
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 191
Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia 191
Reply to “Rituximab activity in CD20-positive multiple myeloma” 189
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 189
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 188
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 188
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 188
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 186
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region 185
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 185
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy 184
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network) 184
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 183
Central Nervous System Multiple Myeloma 182
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 182
Novel agents in CNS myeloma treatment 181
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 177
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 177
Totale 23.203
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.012
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.012
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.272 0 250 172 176 93 99 125 91 125 285 275 581
2022/20233.256 239 225 436 474 281 673 87 246 296 46 187 66
2023/20242.452 105 57 225 133 67 609 846 48 20 68 39 235
2024/20255.856 172 294 555 319 647 372 158 333 479 347 641 1.539
2025/202614.290 1.066 2.034 1.551 1.858 2.423 544 1.332 365 591 713 555 1.258
2026/20271.522 936 586 0 0 0 0 0 0 0 0 0 0
Totale 42.053